Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Arun Sanyal.

Newcastle AuthorsTitleYearFull text
Professor Quentin Anstee
Professor Arun Sanyal
NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials2024
Professor Arun Sanyal
Professor Quentin Anstee
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis2023
Professor Cliff Brass
Professor Arun Sanyal
Professor Quentin Anstee
Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis2023
Professor Arun Sanyal
Professor Quentin Anstee
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis2022
Dr Marie Boyle
Professor Stuart McPherson
Professor Arun Sanyal
Professor Quentin Anstee
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply2022
Professor Quentin Anstee
Professor Arun Sanyal
Noninvasive Evaluation of Response to Obeticholic Acid in Patients with NASH: Results from the REGENERATE Study2022
Professor Helen Reeves
Professor Arun Sanyal
Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865–878]2021
Professor Quentin Anstee
Professor Arun Sanyal
Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study2021
Professor Pierre Bedossa
Professor Quentin Anstee
Professor Arun Sanyal
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study2020
Professor Arun Sanyal
Professor Quentin Anstee
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial2020
Dr Matthew Breckons
Dr Yemi Oluboyede
Professor Luke Vale
Professor Laura Ternent
Professor Arun Sanyal
et al.
Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis2020
Dr Lorraine McSweeney
Dr Matthew Breckons
Dr Gulnar Fattakhova
Professor Luke Vale
Professor Laura Ternent
et al.
Health-Related Quality of Life and Patient-Reported Outcome Measures in NASH-related Cirrhosis2020
Professor Quentin Anstee
Professor Pierre Bedossa
Professor Arun Sanyal
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial2019
Professor Arun Sanyal
Professor Quentin Anstee
Professor Pierre Bedossa
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis2019
Professor Arun Sanyal
Professor Quentin Anstee
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD2019
Professor Quentin Anstee
Professor Chris Day
Professor Arun Sanyal
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-20302018
Professor Quentin Anstee
Professor Arun Sanyal
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum2017
Professor Quentin Anstee
Professor Arun Sanyal
ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial2016
Professor Quentin Anstee
Professor Arun Sanyal
Improvement in NASH histological activity highly correlates with fibrosis regression2016
Professor Quentin Anstee
Professor Arun Sanyal
Validation of mir-34a, mir-122 and mir-200a as bio-markers for identification of NASH patients eligible for treatment2016